$20B from Humira? We're not there yet, and don't count on it in 2019 either: AbbVie CEO

25th January 2019 Uncategorised 0

All eyes were on Humira as AbbVie reported 2018 results: Would it or wouldn’t it break the $20 billion mark as expected? Turns out, the immunology superstar didn’t become the first drug to ever cross that threshold—and it may not in 2019, either.

More: B from Humira? We're not there yet, and don't count on it in 2019 either: AbbVie CEO
Source: fierce